Category: 3. Business

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

• Nebius Group (NasdaqGS:NBIS) is reportedly in advanced talks to acquire Israeli AI startup AI21 Labs.

• The potential deal follows AI21 Labs’ unsuccessful merger discussions with Nvidia.

• The move would extend Nebius beyond AI infrastructure into full stack AI and software.

Nebius Group, trading at around $144.97, has seen very strong share price momentum, with the stock up 33.2% over the past week, 28.3% over the past month and 61.2% year to date. Over the past year, the share price has risen by a very large amount, while the value score of 3 suggests investors may already be paying up for growth and product expansion potential.

If Nebius proceeds with acquiring AI21 Labs, it would be a clear push to widen its offer beyond infrastructure into AI agents and software tools. For investors, a central consideration is whether Nebius can integrate AI21’s products in a way that supports a broader, full stack AI platform and aligns with the recent share price performance of NasdaqGS:NBIS.

Stay updated on the most important news stories for Nebius Group by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Nebius Group.

📰 Beyond the headline: 4 risks and 3 things going right for Nebius Group that every investor should see.

• ⚖️ Price vs Analyst Target: At $144.97, Nebius trades about 10.5% below the US$162 analyst target, suggesting the price is close to consensus with some upside implied.

• ✅ Simply Wall St Valuation: The stock is flagged as undervalued, trading 76.9% below an internal fair value estimate.

• ✅ Recent Momentum: A 30 day return of 28.3% points to strong short term buying interest.

There is only one way to know the right time to buy, sell or hold Nebius Group. Head to Simply Wall St’s company report for the latest analysis of Nebius Group’s fair value.

• 📊 The potential AI21 Labs deal would push Nebius further into full stack AI, so consider how this matches the current valuation signals and the recent share price move.

• 📊 Watch any disclosed deal price, funding mix, impact on margins versus the current 5.5% net income margin, and how analysts adjust the US$162 target range of US$85 to US$291.

• ⚠️ Major risks already flagged include forecast earnings declines and high non cash earnings, which could matter if integration costs or share based compensation rise after an acquisition.

For the full picture including more risks and rewards, check out the complete Nebius Group analysis. Alternatively, you can visit the community page for Nebius Group to see how other investors believe this latest news will impact the company’s narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NBIS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Story Continues

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Fluor (FLR) is drawing investor attention after a period of strong share price performance, with the stock up over the past year and supported by positive revenue and net income growth in the latest annual data.

See our latest analysis for Fluor.

Fluor’s recent 10.34% 1 month share price return and 18.01% year to date share price return sit alongside a 47.87% 1 year total shareholder return, suggesting momentum has been building over both short and longer periods.

If this kind of move has you curious about what else is out there, it could be a good time to scan 30 power grid technology and infrastructure stocks

With Fluor trading at US$49.21 against an analyst price target of US$53.50 and an intrinsic value estimate that sits well above the current share price, you have to ask whether there is a genuine mispricing here or whether the market is already factoring in future growth.

Fluor’s most followed storyline currently points to a fair value of about $54.22 versus the last close at $49.21, and that gap rests on a detailed set of revenue, margin, and valuation assumptions.

Fluor’s shift from revitalizing the capital structure to focusing on generating cash and earnings under its new strategy could drive earnings growth and improve net margins. The strong backlog and significant new awards in life sciences, infrastructure, and key projects in Urban Solutions are expected to boost future revenue and earnings.

Read the complete narrative.

Curious what revenue path, margin profile, and future earnings multiple have to line up to support that price gap? The narrative leans on a detailed road map of project awards, backlog conversion, and earnings power that differs from today’s snapshot, and the assumptions behind it may surprise you.

Result: Fair Value of $54.22 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there is still the risk that project delays and foreign exchange swings could pressure margins and cash flow and could challenge the upbeat earnings narrative around Fluor.

Find out about the key risks to this Fluor narrative.

Our DCF model for Fluor points to a future cash flow value of about $33.70 per share, which sits well below the current $49.21 price and the $54.22 narrative fair value. If the cash flow view is right, is the market leaning too hard on the turnaround story?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Fluor for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

With both risks and rewards in play, do you feel the current story around Fluor really stacks up, or is something missing? Take a moment to weigh the data, act while sentiment is still forming, and look closely at the 2 key rewards and 1 important warning sign

If Fluor has sharpened your focus, do not stop here. Use these curated stock ideas to turn that momentum into a broader, well-checked watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include FLR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

• Diebold Nixdorf (NYSE:DBD) has been added to the S&P SmallCap 600, S&P Composite 1500, S&P 1000, and S&P 600 Information Technology indices.

• The index changes recognize the company’s progress and expand its potential exposure to index-linked funds.

• Separately, Diebold Nixdorf has partnered with FOREX to modernize and operate ATM channels across the Nordic countries.

• The FOREX agreement uses the company’s SMART Managed Services and Vynamic Software platform to deliver managed ATM services in Scandinavia.

Diebold Nixdorf, a provider of banking and retail technology solutions, sits at the intersection of software, services, and physical cash access. As banks and financial institutions reassess branch networks and self service channels, managed ATM services and software led platforms have drawn more attention. The FOREX partnership gives investors a fresh data point on how NYSE:DBD is positioning within that part of the payments and cash access ecosystem.

The new S&P index inclusions put NYSE:DBD on the radar of investors who track or use small cap and information technology benchmarks. For readers, the key questions now center on how effectively the company executes on the FOREX agreement and similar deals, and how that operational track record feeds into liquidity, trading interest, and future business opportunities.

Stay updated on the most important news stories for Diebold Nixdorf by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Diebold Nixdorf.

See which insiders are buying and buying and selling Diebold Nixdorf following this latest news.

• ⚖️ Price vs Analyst Target: At US$84.78, the share price is about 12% below the US$96.67 analyst target, suggesting it is trading slightly under consensus expectations.

• ✅ Simply Wall St Valuation: Simply Wall St’s model suggests the stock is trading roughly 57.5% below its estimated fair value, which flags a potential value gap.

• ✅ Recent Momentum: A 30 day return of about 12.7% shows buyers have already reacted positively to recent developments.

There is only one way to know the right time to buy, sell or hold Diebold Nixdorf. Head to Simply Wall St’s company report for the latest analysis of Diebold Nixdorf’s Fair Value.

• 📊 Index inclusion can widen the potential investor base and improve liquidity. The FOREX deal also gives more evidence of demand for Diebold Nixdorf’s managed services and software.

• 📊 Keep an eye on how revenue, margins and cash flows from ATM and software contracts in the Nordics feed through to earnings. Compare this against the current P/E of 31.2 and forward P/E of 16.3.

• ⚠️ The company carries a high level of debt and has had large one off items in its results. Funding terms and cash generation therefore remain key risks to track alongside this growth story.

For the full picture including more risks and rewards, check out the complete Diebold Nixdorf analysis. Alternatively, you can check out the community page for Diebold Nixdorf to see how other investors believe this latest news will impact the company’s narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include DBD.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

• Anthropic recently introduced Managed Agents, a new service that can run autonomous AI workflows for businesses.

• This model could reduce the need for traditional seat-based software subscriptions that charge per user.

• Doximity (NYSE:DOCS), which relies heavily on a SaaS model for clinicians and life sciences customers, could face a new type of competitive pressure.

Doximity runs a digital platform for U.S. clinicians, combining professional networking, telehealth tools, and workflow software under a subscription model. At the same time, large AI providers are starting to offer plug and play infrastructure such as Anthropic’s Managed Agents that lets enterprises automate tasks directly on top of their data and systems. For NYSE:DOCS, that shift raises questions around how much value sits in its software interface versus what could be handled by more generic AI orchestration.

For you as an investor, the key issue is how AI infrastructure like Managed Agents might change customer expectations around pricing, integration, and flexibility. The story here is less about near term numbers and more about whether Doximity can keep its tools essential if clients can increasingly spin up autonomous AI workflows without relying as heavily on seat based SaaS platforms.

Stay updated on the most important news stories for Doximity by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Doximity.

📰 Beyond the headline: 0 risks and 4 things going right for Doximity that every investor should see.

• ✅ Price vs Analyst Target: At US$21.05, Doximity trades about 46% below the US$39.05 analyst price target.

• ✅ Simply Wall St Valuation: Shares are flagged as trading 57.8% below the estimated fair value.

• ❌ Recent Momentum: The 30 day return is about a 14.6% decline.

To assess whether it may be the right time to buy, sell or hold Doximity, you can review Simply Wall St’s company report for the latest analysis of Doximity’s fair value.

• 📊 Managed Agents style AI services could pressure Doximity’s seat based SaaS model if customers shift more workflows to generic automation platforms.

• 📊 It may be useful to monitor how pricing, contract terms and usage patterns evolve, along with any AI feature releases or partnerships that integrate Doximity more closely into clinician workflows.

• ⚠️ A key risk is that generic AI orchestration reduces customer reliance on Doximity’s interface, which could affect its ability to defend margins and subscription economics.

For a broader view, including additional risks and potential rewards, you can review the complete Doximity analysis. You can also visit the community page for Doximity to see how other investors believe this latest news may influence the company’s narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include DOCS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Story Continues

Story Continues

A “normal” or “fair” P/E typically reflects what investors expect for future growth and how much risk they see in the business. Higher expected earnings growth or lower perceived risk can support a higher P/E, while lower growth expectations or higher risk usually align with a lower P/E.

Solvay currently trades on a P/E of 98.84x. That is above the Chemicals industry average of 23.01x and the peer group average of 16.77x. Simply Wall St also calculates a proprietary “Fair Ratio” of 39.74x for Solvay. This metric aims to capture what P/E might be reasonable for the company given factors such as its earnings growth profile, industry, profit margin, market cap and risk characteristics.

This Fair Ratio can be more informative than a simple peer or industry comparison, because it attempts to adjust for Solvay specific traits rather than assuming all chemicals companies deserve similar multiples. Comparing Solvay’s current P/E of 98.84x with the Fair Ratio of 39.74x indicates that the shares look expensive on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 97 top founder-led companies.

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as simple stories you choose about Solvay that connect your view of its business, such as whether it looks closer to the €20.0 bearish case or the €37.0 bullish case, to a set of explicit forecasts for revenue, earnings and margins. These then feed into a Fair Value that you can compare with the current price to help decide whether to act, all within an accessible tool on Simply Wall St’s Community page that continuously refreshes as new news or earnings arrive so your Solvay view always reflects the latest information.

For Solvay however we’ll make it really easy for you with previews of two leading Solvay Narratives:

🐂 Solvay Bull Case

Fair value used in this bullish narrative: €37.00 per share.

Implied discount to this fair value at the last close of €28.38: about 23% below the narrative fair value.

Revenue trend assumption in this narrative: 62% annual decline in revenue.

• Focuses on cost restructuring, digital tools and energy transition projects that are expected to support wider margins and stronger free cash flow even if volumes stay soft.

• Builds in higher earnings by 2028, with profit margins rising into double digits and a lower future P/E of 9.6x compared with today.

• Assumes a bullish analyst price target of €37.00, with the view that this is justified if Solvay meets those earnings, margin and cash flow expectations.

🐻 Solvay Bear Case

Fair value used in this more cautious narrative: €25.47 per share.

Implied premium to this fair value at the last close of €28.38: about 11% above the narrative fair value.

Revenue trend assumption in this narrative: 2.54% annual revenue decline.

• Highlights softer revenue expectations, pricing pressure in soda ash and Coatis, and ongoing environmental cash outflows that weigh on earnings and free cash flow.

• Builds in margin improvement to 6.9% and earnings of €305.1m by 2029, but with a future P/E of 11.0x that is well below today’s multiple.

• Anchors on a consensus fair value around €25.47, with analyst targets ranging from €20.00 to €33.00 and indicating that, on this view, Solvay is close to fairly priced.

Whichever story feels closer to your own view of Solvay, the key is to sanity check the revenue, margin and P/E assumptions rather than just focusing on the share price headline.

See what the community is saying about Solvay

Do you think there’s more to the story for Solvay? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SOLB.BR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

NOW Corporation (PSE:NOW) has drawn fresh attention after recent trading left the share price at ₱0.56, with returns mixed across different periods and an intrinsic value metric suggesting a premium to estimated worth.

See our latest analysis for NOW.

Recent trading has been choppy, with a 1-day share price return of 1.82% and a 7-day gain of 5.66% sitting against a 90-day share price return of 18.84% and a year to date decline of 20.00%. The 1-year total shareholder return of 40.00% contrasts with steeper 3 and 5 year total shareholder return declines. This points to improving short term momentum on a longer weak record and a share price that currently sits above one intrinsic value estimate.

If NOW’s recent swings have you thinking about where else growth and risk might line up differently, it could be a good time to widen your search with 95 top founder-led companies

With the share price sitting at ₱0.56, trading above one intrinsic value estimate and recent returns mixed across timeframes, the key question now is whether NOW is still undervalued or if the market is already pricing in future growth.

NOW’s shares trade at ₱0.56, and the company carries a P/S ratio of 7.3x, which sits well above both industry and peer averages.

The P/S ratio compares the market value of the company to its annual revenue. For a business like NOW, which currently reports a loss of ₱8.10m on revenue of ₱138.38m, this metric focuses attention on what investors are paying for each peso of sales rather than profits that are not yet in place.

Here, the key tension is that earnings have declined by 20.8% per year over the past 5 years and the company is still unprofitable. However, the share price implies a much richer revenue multiple. With no meaningful profit track record and no available earnings or revenue forecasts, a high P/S ratio suggests the market is pricing in expectations that are not visible in the historical numbers provided.

Compared to the Asian IT industry average P/S of 1.5x and a peer average of 1.2x, NOW’s 7.3x multiple is sharply higher. This indicates that the stock is valued at several times the revenue multiple of its sector and closest comparables.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-sales of 7.3x (OVERVALUED)

However, the loss of ₱8.10m on revenue of ₱138.38m and a 5 year total return decline of 80.28% show that sentiment could shift quickly if expectations change.

Find out about the key risks to this NOW narrative.

While the 7.3x P/S ratio already looks rich versus the Asian IT industry and peers, the SWS DCF model also points to a stretched valuation. With NOW trading at ₱0.56 against an estimated future cash flow value of ₱0.23, this approach also signals an overvalued share price. The question is which view you trust more.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out NOW for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 231 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

If you are concerned that this feels one sided or overly cautious, review the underlying figures yourself and consider the 2 important warning signs.

NOW might be on your radar, but some of the most interesting opportunities sit just outside the headlines, so it pays to scan the wider market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NOW.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com